Aladdin Ali Deeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aladdin Ali Deeb has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Felix Dondorf
Klinik für Allgemein‑, Viszeral- und Gefäßchirurgie, Universitätsklinikum Jena, Jena, Deutschland
11 shared publications - Utz Settmacher
Klinik für Allgemein‑, Viszeral- und Gefäßchirurgie, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Deutschland.
11 shared publications - Falk Rauchfuss
Department of General, Visceral and Vascular Surgery, Jena University Hospital, 07747 Jena, Germany
10 shared publications - Oliver Rohland
Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany
10 shared publications Utz Settmacher
Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany
7 shared publications- Laura Schwenk
Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101211
Decision regret in patients with rectal cancer undergoing multimodal therapy
- 1 June 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101211
Open AccessDecision regret in patients with rectal cancer undergoing multimodal therapy
- Open Access
The Impact of Local Ablative Therapies as Bridging Treatment on Overall Survival Following Liver Transplantation in Patients with HCC
Background: The use of neoadjuvant therapies in patients with hepatocellular carcinoma prior to liver transplantation has gained increasing popularity in recent years. To date, there are only limited data investigating the impact of neoadjuvant therapy on post-transplant survival. Methods: In this retrospective study, we evaluated patients with hepatocellular carcinoma who underwent deceased donor or living donor liver transplantation at Jena University Hospital between 2019 and 2023. Comprehensive clinical and pathological variables were systematically analyzed, including correlations between neoadjuvant therapy use, tumor burden and overall survival. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 107 patients were included in the analysis, of whom 90 received neoadjuvant therapy prior to transplantation. Treatment modalities comprised SIRT, TACE, liver resection and combined SIRT and TACE. The 1-, 3-, and 5-year OS rates following transplantation were 93.5%, 82.2%, and 79.4%, respectively. Recurrence-free survival at 1, 3, and 5 years was 91.6%, 85.0%, and 83.2%, respectively. Among the various neoadjuvant strategies, SIRT and TACE yielded the highest OS rates. Patients listed outside the transplantation criteria (Milan, UCSF, up-to-seven) at the time of initial diagnosis who underwent SIRT had significantly better OS than those outside the criteria who underwent TACE. In contrast, among patients within the Milan, UCSF and up-to-seven criteria, TACE was associated with superior OS compared with SIRT. Conclusion: The use of neoadjuvant therapies confers a significant survival benefit following liver transplantation in patients with HCC. TACE appears to be most suitable for patients listed within established transplantation criteria, who consequently have a lower tumor burden. In contrast, SIRT is more beneficial for patients with a higher tumor burden and those beyond standard transplantation criteria. A limitation of our study, however, is that the included SIRT cohort comprised only 24 patients, and TACE was preferentially performed in patients with a lower tumor burden, which means that a selection bias cannot be fully excluded. Overall, further studies are required to define the optimal bridging strategies.
Open AccessThe Impact of Local Ablative Therapies as Bridging Treatment on Overall Survival Following Liver Transplantation in Patients with HCC
Background: The use of neoadjuvant therapies in patients with hepatocellular carcinoma prior to liver transplantation has gained increasing popularity in recent years. To date, there are only limited data investigating the impact of neoadjuvant therapy on post-transplant survival. Methods: In this retrospective study, we evaluated patients with hepatocellular carcinoma who underwent deceased donor or living donor liver transplantation at Jena University Hospital between 2019 and 2023. Comprehensive clinical and pathological variables were systematically analyzed, including correlations between neoadjuvant therapy use, tumor burden and overall survival. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 107 patients were included in the analysis, of whom 90 received neoadjuvant therapy prior to transplantation. Treatment modalities comprised SIRT, TACE, liver resection and combined SIRT and TACE. The 1-, 3-, and 5-year OS rates following transplantation were 93.5%, 82.2%, and 79.4%, respectively. Recurrence-free survival at 1, 3, and 5 years was 91.6%, 85.0%, and 83.2%, respectively. Among the various neoadjuvant strategies, SIRT and TACE yielded the highest OS rates. Patients listed outside the transplantation criteria (Milan, UCSF, up-to-seven) at the time of initial diagnosis who underwent SIRT had significantly better OS than those outside the criteria who underwent TACE. In contrast, among patients within the Milan, UCSF and up-to-seven criteria, TACE was associated with superior OS compared with SIRT. Conclusion: The use of neoadjuvant therapies confers a significant survival benefit following liver transplantation in patients with HCC. TACE appears to be most suitable for patients listed within established transplantation criteria, who consequently have a lower tumor burden. In contrast, SIRT is more beneficial for patients with a higher tumor burden and those beyond standard transplantation criteria. A limitation of our study, however, is that the included SIRT cohort comprised only 24 patients, and TACE was preferentially performed in patients with a lower tumor burden, which means that a selection bias cannot be fully excluded. Overall, further studies are required to define the optimal bridging strategies.
- 25 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , 656-668
Liver transplantation in well-selected patients with unresectable colorectal liver metastases
Liver transplantation may be a curative treatment option in patients with otherwise unresectable liver metastases. We sought to evaluate the long-term outcomes of transplantation candidates by comparing 2 groups: one treated with living-donor liver transplantation and the other, due to the absence of available living donors, receiving the current gold standard of chemotherapy only. Eligibility for inclusion of patients with unresectable liver metastases required either stable disease or tumor regression after systemic chemotherapy with no extrahepatic tumor burden. Patients were divided into 2 cohorts according to the availability of a suitable living donor. The fundamental technical principle is a 2-stage transplantation procedure, also referred to as the RAPID technique (Resection and Partial Liver Transplantation with Delayed Hepatectomy). In the first operation, a left hemihepatectomy is carried out in the recipient, followed by orthotopic transplantation of the left lateral liver lobe (segments II and III) from a living donor. To promote graft hypertrophy, portal vein ligation is undertaken. In the second step of the operation, the remaining right lobe of the liver will be removed. The 3-year and 5-year survival rates for the transplantation group were 71.3% and 57%, respectively, compared with 33.3% and 11.1%, respectively, for 15 patients with a negative donor evaluation. The recurrence rate among transplanted patients was 58%. The median disease-free survival time between liver transplantation and recurrence or death was 17.4 months. For those who experienced a recurrence, the median survival time from recurrence was 25.6 months. Liver transplantation for patients with unresectable colorectal liver metastases leads to a significant survival advantage compared with chemotherapy alone. Living-donor liver transplantation is a suitable and safe method to expand organ availability for selected patients.
- 25 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , 656-668
Liver transplantation in well-selected patients with unresectable colorectal liver metastases
Liver transplantation may be a curative treatment option in patients with otherwise unresectable liver metastases. We sought to evaluate the long-term outcomes of transplantation candidates by comparing 2 groups: one treated with living-donor liver transplantation and the other, due to the absence of available living donors, receiving the current gold standard of chemotherapy only. Eligibility for inclusion of patients with unresectable liver metastases required either stable disease or tumor regression after systemic chemotherapy with no extrahepatic tumor burden. Patients were divided into 2 cohorts according to the availability of a suitable living donor. The fundamental technical principle is a 2-stage transplantation procedure, also referred to as the RAPID technique (Resection and Partial Liver Transplantation with Delayed Hepatectomy). In the first operation, a left hemihepatectomy is carried out in the recipient, followed by orthotopic transplantation of the left lateral liver lobe (segments II and III) from a living donor. To promote graft hypertrophy, portal vein ligation is undertaken. In the second step of the operation, the remaining right lobe of the liver will be removed. The 3-year and 5-year survival rates for the transplantation group were 71.3% and 57%, respectively, compared with 33.3% and 11.1%, respectively, for 15 patients with a negative donor evaluation. The recurrence rate among transplanted patients was 58%. The median disease-free survival time between liver transplantation and recurrence or death was 17.4 months. For those who experienced a recurrence, the median survival time from recurrence was 25.6 months. Liver transplantation for patients with unresectable colorectal liver metastases leads to a significant survival advantage compared with chemotherapy alone. Living-donor liver transplantation is a suitable and safe method to expand organ availability for selected patients.
- Open Access
- 14 June 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-7
Long term results and quality of life after primary excision followed by Limberg plasty in pilonidal sinus disease
Background: Pilonidal sinus disease (PSD) is a frequently occurring condition that can have a significant impact on quality of life (QoL). In addition to severe pain, particularly with movement or while sitting, this disease imposes restrictions that affect one’s professional and private life. These patients frequently suffer from recurrence requiring multiple interventions and hospital stays. Methods: The study enrolled forty-seven patients who presented with PSD from August 2010 until June 2019 and underwent primary excision and LP at the Department of General, Visceral, and Vascular Surgery at University Hospital, Jena. Forty- one of these patients were questioned retrospectively in writing or by telephone interviews between July 2021 to September 2022. The data processed using SPSS software. Results: The median follow-up for all patients was 86 months (range, 23–140 months). Only one recurrence (2.4%) was reported. While the participants’ BMIs remained unchanged, they reported significant improvements in QoL, notably in five of the six activities of daily living that were evaluated. Conclusion: The low rate of recurrence suggests that LP is an effective option for post-excision surgical repair of pilonidal sinus. The use of this procedure has no impact on patient’s BMI but can significantly improve patients’ QoL.
- 14 June 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-7
Open AccessLong term results and quality of life after primary excision followed by Limberg plasty in pilonidal sinus disease
Background: Pilonidal sinus disease (PSD) is a frequently occurring condition that can have a significant impact on quality of life (QoL). In addition to severe pain, particularly with movement or while sitting, this disease imposes restrictions that affect one’s professional and private life. These patients frequently suffer from recurrence requiring multiple interventions and hospital stays. Methods: The study enrolled forty-seven patients who presented with PSD from August 2010 until June 2019 and underwent primary excision and LP at the Department of General, Visceral, and Vascular Surgery at University Hospital, Jena. Forty- one of these patients were questioned retrospectively in writing or by telephone interviews between July 2021 to September 2022. The data processed using SPSS software. Results: The median follow-up for all patients was 86 months (range, 23–140 months). Only one recurrence (2.4%) was reported. While the participants’ BMIs remained unchanged, they reported significant improvements in QoL, notably in five of the six activities of daily living that were evaluated. Conclusion: The low rate of recurrence suggests that LP is an effective option for post-excision surgical repair of pilonidal sinus. The use of this procedure has no impact on patient’s BMI but can significantly improve patients’ QoL.
- Open Access
- 21 May 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-15
The impact of serum ferritin on overall survival following resection in patients with intrahepatic cholangiocarcinoma
Purpose: The global incidence of intrahepatic cholangiocarcinoma is increasing. Surgical resection remains the gold standard treatment. However, the long-term prognosis remains dismal. The role of serum ferritin in malignant diseases has not been fully elucidated. This study aimed to evaluate the relationship between preoperative serum ferritin levels and patient outcomes. Methods: In our retrospective study, we analyzed data from 95 patients who underwent liver resection for intrahepatic cholangiocarcinoma at Jena University Hospital between 2009 and 2023. Comprehensive clinical and pathological data, along with the correlation between Serum ferritin and clinicopathological parameters, were systematically analyzed and compared. Survival rates were determined using the Kaplan-Meier method. Results: The optimal preoperative serum ferritin cut-off value for overall survival was 303.1 µg/L, with an area under the curve of 0.697 (95% CI (0.592–0.801; P < 0.001). The 1-, 3-, and 5-year survival rates were 74.7%, 50.5%, and 43.2%, respectively. Patients with elevated preoperative SF levels demonstrated significantly worse overall survival compared to the low SF group (50.9% vs. 4.5%; P < 0.001). SF had a significant impact on recurrence rates (P < 0.001). The overall recurrence rate in the high-SF group was 67,3%, compared to 43,5% in the low-SF group. Conclusion: Elevated preoperative serum ferritin levels are associated with significantly worse overall and recurrence-free survival in patients with intrahepatic cholangiocarcinoma. Serum ferritin could serve as a valuable adjunct to the tumor marker CA 19 − 9.
- 21 May 2025
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-15
Open AccessThe impact of serum ferritin on overall survival following resection in patients with intrahepatic cholangiocarcinoma
Purpose: The global incidence of intrahepatic cholangiocarcinoma is increasing. Surgical resection remains the gold standard treatment. However, the long-term prognosis remains dismal. The role of serum ferritin in malignant diseases has not been fully elucidated. This study aimed to evaluate the relationship between preoperative serum ferritin levels and patient outcomes. Methods: In our retrospective study, we analyzed data from 95 patients who underwent liver resection for intrahepatic cholangiocarcinoma at Jena University Hospital between 2009 and 2023. Comprehensive clinical and pathological data, along with the correlation between Serum ferritin and clinicopathological parameters, were systematically analyzed and compared. Survival rates were determined using the Kaplan-Meier method. Results: The optimal preoperative serum ferritin cut-off value for overall survival was 303.1 µg/L, with an area under the curve of 0.697 (95% CI (0.592–0.801; P < 0.001). The 1-, 3-, and 5-year survival rates were 74.7%, 50.5%, and 43.2%, respectively. Patients with elevated preoperative SF levels demonstrated significantly worse overall survival compared to the low SF group (50.9% vs. 4.5%; P < 0.001). SF had a significant impact on recurrence rates (P < 0.001). The overall recurrence rate in the high-SF group was 67,3%, compared to 43,5% in the low-SF group. Conclusion: Elevated preoperative serum ferritin levels are associated with significantly worse overall and recurrence-free survival in patients with intrahepatic cholangiocarcinoma. Serum ferritin could serve as a valuable adjunct to the tumor marker CA 19 − 9.
- 18 February 2025
- Published by Springer Nature in Die Chirurgie
- p. 1-6
Langzeitergebnisse einer Pilotstudie über das zweizeitige Verfahren mit primärer Exzision und Limberg-Plastik im Intervall zur Therapie einer sakrokokzygealen Pilonidalsinuserkrankung
Zusammenfassung Hintergrund In der aktuellen AWMF-S3-Leitlinie wird unter anderen plastischen Verfahren die Limberg-Plastik zur Behandlung der Pilonidalsinuserkrankung empfohlen. In der aktuellen Arbeit sollen die Langzeitergebnisse der Pilotstudie „Ergebnisse eines zweizeitigen Verfahrens mit primärer Exzision und Limberg-Plastik im Intervall zur Therapie einer sakrokokzygealen Pilonidalsinuserkrankung“ dargestellt werden, die 2015 publiziert wurde. Methodik Im Zeitraum von 2010 bis 2013 wurden 50 Patienten mit einer sakrokokzygealen Pilonidalsinuserkrankung behandelt. Nach initialer Exzision wurde den Patienten eine plastische Deckung nach Vorliegen sauberer Wundverhältnisse gemäß der damals gültigen AWMF-Leitlinie im Primärfall angeboten und im Rezidivfall empfohlen. 22 Patienten entschieden sich für eine Limberg-Plastik. Im Jahr 2022 erfolgte eine Erhebung der Rezidive durch ein telefonisches Interview mit den Patienten. Es erfolgte ein Vergleich der Gruppen mit Limberg-Plastik mit der Gruppe der Exzision. Ergebnisse In der Limberg-Plastik-Gruppe fand sich kein Rezidiv (0%), wohingegen sich in der Exzisionsgruppe 6 Rezidive fanden (23%; p = 0,028). In der Limberg-Gruppe konnte ein Patient und in der Exzisionsgruppe 2 Patienten für die Nachuntersuchung nicht erreicht werden. Fazit Durch das zweizeitige Verfahren wird die Limberg-Plastik bei entzündungsfreien Wundverhältnissen offensichtlich effektiver. Die Limberg-Plastik ist ein einfaches plastisches Verfahren, jedoch sollte man bedenken, dass es sich dabei um einen Transpositionslappen handelt. Graphic abstract
- 18 February 2025
- Published by Springer Nature in Die Chirurgie
- p. 1-6
Langzeitergebnisse einer Pilotstudie über das zweizeitige Verfahren mit primärer Exzision und Limberg-Plastik im Intervall zur Therapie einer sakrokokzygealen Pilonidalsinuserkrankung
Zusammenfassung Hintergrund In der aktuellen AWMF-S3-Leitlinie wird unter anderen plastischen Verfahren die Limberg-Plastik zur Behandlung der Pilonidalsinuserkrankung empfohlen. In der aktuellen Arbeit sollen die Langzeitergebnisse der Pilotstudie „Ergebnisse eines zweizeitigen Verfahrens mit primärer Exzision und Limberg-Plastik im Intervall zur Therapie einer sakrokokzygealen Pilonidalsinuserkrankung“ dargestellt werden, die 2015 publiziert wurde. Methodik Im Zeitraum von 2010 bis 2013 wurden 50 Patienten mit einer sakrokokzygealen Pilonidalsinuserkrankung behandelt. Nach initialer Exzision wurde den Patienten eine plastische Deckung nach Vorliegen sauberer Wundverhältnisse gemäß der damals gültigen AWMF-Leitlinie im Primärfall angeboten und im Rezidivfall empfohlen. 22 Patienten entschieden sich für eine Limberg-Plastik. Im Jahr 2022 erfolgte eine Erhebung der Rezidive durch ein telefonisches Interview mit den Patienten. Es erfolgte ein Vergleich der Gruppen mit Limberg-Plastik mit der Gruppe der Exzision. Ergebnisse In der Limberg-Plastik-Gruppe fand sich kein Rezidiv (0%), wohingegen sich in der Exzisionsgruppe 6 Rezidive fanden (23%; p = 0,028). In der Limberg-Gruppe konnte ein Patient und in der Exzisionsgruppe 2 Patienten für die Nachuntersuchung nicht erreicht werden. Fazit Durch das zweizeitige Verfahren wird die Limberg-Plastik bei entzündungsfreien Wundverhältnissen offensichtlich effektiver. Die Limberg-Plastik ist ein einfaches plastisches Verfahren, jedoch sollte man bedenken, dass es sich dabei um einen Transpositionslappen handelt. Graphic abstract
- Open Access
- 2 July 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e944518-e944518-10
Adipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation in Non-Obese Recipients
Adipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation in Non-Obese Recipients - Article abstract #944518
- 2 July 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e944518-e944518-10
Open AccessAdipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation in Non-Obese Recipients
Adipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation in Non-Obese Recipients - Article abstract #944518
- 3 June 2024
- Published by Springer Nature in Die Chirurgie
- Vol. 95 (8) , 632-637
Die Rolle des muskuloadipösen Status bei der Beurteilung des Risikoprofils vor Lebertransplantation
Zusammenfassung Sowohl Sarkopenie als auch die sarkopenische Adipositas beeinträchtigen die Prognose nach Lebertransplantation. Die Einschätzung der Körperzusammensetzung wird jedoch zur Abschätzung des Risikoprofils des Empfängers in der Evaluation vor Lebertransplantation noch nicht berücksichtigt. Prähabilitation, die Nahrungsergänzung und Physiotherapie umfasst, ist ein neuer Schwerpunkt der klinischen Transplantationsforschung. Hier wird ein Überblick über die neuesten Erkenntnisse über die Rolle des muskuloadipösen Status und die verfügbaren Methoden zu dessen Assessment bei der Beurteilung des Risikoprofils des Empfängers gegeben.
- 3 June 2024
- Published by Springer Nature in Die Chirurgie
- Vol. 95 (8) , 632-637
Die Rolle des muskuloadipösen Status bei der Beurteilung des Risikoprofils vor Lebertransplantation
Zusammenfassung Sowohl Sarkopenie als auch die sarkopenische Adipositas beeinträchtigen die Prognose nach Lebertransplantation. Die Einschätzung der Körperzusammensetzung wird jedoch zur Abschätzung des Risikoprofils des Empfängers in der Evaluation vor Lebertransplantation noch nicht berücksichtigt. Prähabilitation, die Nahrungsergänzung und Physiotherapie umfasst, ist ein neuer Schwerpunkt der klinischen Transplantationsforschung. Hier wird ein Überblick über die neuesten Erkenntnisse über die Rolle des muskuloadipösen Status und die verfügbaren Methoden zu dessen Assessment bei der Beurteilung des Risikoprofils des Empfängers gegeben.
- Open Access
Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy
Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.
Open AccessLiver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy
Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.
- Open Access
- 22 January 2024
- Published by MDPI AG in Preprints.org
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria
Purpose: This study aimed to elucidate the various new classifications and the use of LDLT in this context for HCC beyond milan criteria. Methods: The clinical data of patients with HCC outside milan criteria who underwent LT at Jena University between Januar 2007 and August 2023 were retrospectively analyzed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall- and disease-free survival rates were compared between the two groups (LT vs. LDLT) and in context for bridging therapy. Results: Among the 245 patients analyzed, 120 patients were outside milan criteria and 125 patients were inside milan. There was no significant difference for patients outside milan in overall survival for LT versus LDLT (OS 44,3 months vs. 28,3 months; 5y survival, 56,4% vs. 40%; p = 0.84). G3 tumor differentiation, presence of angioinvasion and lack of bridging were statistically significant risk factors predicting tumor recurrence in univariate and multivariate analysis (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provides a significant survival advantage regardless of the transplant procedure (OS: p = 0.008 ; DFS: p < 0.001). Conclusions: Patients with HCC outside milan criteria who underwent LT or LDLT had comparable outcome to patients inside milan criteria. Nevertheless, these patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients depending on tumor differentiation, size and tumor marker dynamics.
- 22 January 2024
- Published by MDPI AG in Preprints.org
Open AccessLiver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria
Purpose: This study aimed to elucidate the various new classifications and the use of LDLT in this context for HCC beyond milan criteria. Methods: The clinical data of patients with HCC outside milan criteria who underwent LT at Jena University between Januar 2007 and August 2023 were retrospectively analyzed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall- and disease-free survival rates were compared between the two groups (LT vs. LDLT) and in context for bridging therapy. Results: Among the 245 patients analyzed, 120 patients were outside milan criteria and 125 patients were inside milan. There was no significant difference for patients outside milan in overall survival for LT versus LDLT (OS 44,3 months vs. 28,3 months; 5y survival, 56,4% vs. 40%; p = 0.84). G3 tumor differentiation, presence of angioinvasion and lack of bridging were statistically significant risk factors predicting tumor recurrence in univariate and multivariate analysis (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provides a significant survival advantage regardless of the transplant procedure (OS: p = 0.008 ; DFS: p < 0.001). Conclusions: Patients with HCC outside milan criteria who underwent LT or LDLT had comparable outcome to patients inside milan criteria. Nevertheless, these patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients depending on tumor differentiation, size and tumor marker dynamics.